PADA-1: A randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA ESR1 mutation monitoring in ER-positive, HER2-negative metastatic breast cancer

Affiliation auteurs!!!! Error affiliation !!!!
TitrePADA-1: A randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA ESR1 mutation monitoring in ER-positive, HER2-negative metastatic breast cancer
Type de publicationJournal Article
Year of Publication2018
AuteursBidard FClement, Sabatier R, Berger F, Pistilli B, Dalenc F, Rouge TDe la Mott, Frenel J-S, Dubot C, Ladoire S, Ferrero J-M, Stefani L, Lortholary A, Hardy-Bessard A-C, Grenier J, Everhard S, Jeannot E, Proudhon C, Lemonnier J, Delaloge S, Bachelot TDenis
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume36
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2018.36.15_suppl.TPS1105